At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,428 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Insulin Lispro (U100) for Type 2 Diabetes. Completed, enrolled 1,428 participants across 135 sites in 16 countries.
Detailed Summary
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesArgentina, Belgium, Brazil, Czechia, Germany, Greece, Hungary, Italy, Mexico, Puerto Rico, Romania, Russia, Slovakia, Spain, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionOct 2022
Study CompletionNov 2022
TodayJul 2026
First PostedSep 3, 2020
Enrollment StartOct 19, 2020
Primary CompletionOct 11, 2022
Study CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.8 years ago
Interventions
Tirzepatidedrug
Administered SC
Insulin Lispro (U100)drug
Administered SC